Outsourcing-Pharma: FHI Clinical, Oracle partner on cloud-based trial tech

October 20, 2020

Rob King, Chief Operating Officer at FHI Clinical, recently spoke with Jenni Spinner, editor for Outsourcing-Pharma, about the company’s partnership with Oracle Health Sciences to create a solution capable of meeting challenges tied to starting and conducting global clinical trials. Rob explained the goal of the partnership is to deliver the best technology possible to researchers that typically receive the least support but have the greatest potential impact on human development.

Chief Operating Officer

“We wanted the average user to be able to set-up, access and generate the data they need without the assistance of experienced programmers. Particularly, we wanted systems that could be used in resource-limited settings that were not only easy to use but also priced at a lower cost point.”

FHI Clinical selected the Oracle Clinical One cloud platform because of the following features:

  • Cloud-based
  • Modular
  • No experienced programmer support required
  • Single, central database
  • Low price point

For more information, check out the Outsourcing-Pharma article.

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post